bs-1355R-Cy3 [Conjugated Primary Antibody]
TANK Polyclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: TANK

Immunogen Range: 151-260/425


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 10010

Source: KLH conjugated synthetic peptide derived from human TANK

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

TANK was initially identified as a novel TRAF-interacting protein that regulated TRAF-mediated signal transduction. Specifically, ligand binding by surface receptors in the tumor necrosis factor (TNF) receptor and Toll/interleukin-1 (IL-1) receptor families lead to the formation of a TRAF/TANK complex that mediates the activation of the transcription factor NF-kappaB. TANK is found in the cytoplasm and can bind to TRAF1, TRAF2, or TRAF3, thereby inhibiting TRAF function by sequestering the TRAFs in a latent state in the cytoplasm. For example, this protein can block TRAF2 binding to LMP1, the Epstein Barr virus transforming protein, and inhibit LMP1-mediated NF kappa B activation.

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 48


Predicted Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Shasha Li. et al. TANK shapes an immunosuppressive microenvironment and predicts prognosis and therapeutic response in glioma. FRONT IMMUNOL. 2023; 14: 1138203Read more>>